Today Boehringer Ingelheim formally acquired Amgen’s biopharmaceutical
development and manufacturing facility in Fremont,
California. This acquisition
involves leasing buildings, acquiring physical equipment and assuming
manufacturing processes done at the Fremont
site. The state-of-the-art facility currently employs more than 300 employees
and consists of more than 200,000 square feet for laboratories, manufacturing
and process development suitable for clinical and market supplies. The purchase
agreement was signed in January 2011. The companies agreed not to disclose
details of the purchase price.
“Presence in Fremont,
CA aligns with our growth
strategy in several ways,” said Simon Sturge, Corporate Senior Vice
President Biopharmaceuticals, Boehringer Ingelheim GmbH. “The strategic
decision to have a state–of-the-art contract manufacturing facility in the U.S.
Bay Area biotechnology cluster will give Boehringer Ingelheim a greater
opportunity to serve current and future customers. In addition the
technological expertise present at Fremont
will complement our goal to further increase Boehringer Ingelheim’s world
leading position in the process development and manufacture of
Biopharmaceuticals.”
As a fully integrated manufacturing site, the Fremont site complements
the existing capabilities and technology found across the existing Boehringer
Ingelheim biopharma network located in Biberach/Germany and Vienna/Austria.
Boehringer Ingelheim has been a contract manufacturer for
Amgen for ten years and will continue to support Amgen’s delivery of safe and
effective medicines to patients around the world. “We look forward to our
continued contract manufacturing partnership with Amgen,” said Simon
Sturge.
The Boehringer Ingelheim contract manufacturing portfolio
includes sixteen licensed biopharmaceuticals manufactured in globally licensed
multi-product facilities, a growing pipeline of New Biological Entities (NBEs),
and a growth strategy in the Contract Manufacturing Business (CMB). Boehringer
Ingelheim’s objective is to remain a leader in Contract Manufacturing as an
industry benchmark for operational excellence including technical expertise and
state-of-the-art technology.
